Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

Completed · Phase 2

Conditions studied: Covid19, Long COVID-19, Post-COVID-19 Syndrome

In brief

Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.

Key facts

Study ID

NCT04604704

Run by

AgelessRx

People needed

36

Starts

2021-01-28

Expected to finish

2023-01-23

Last updated by the study team

2023-01-25

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any ethnicity
• Adequate cognitive function to be able to give informed consent
• Technologically competent to complete web forms and perform video calls with the PI
• Positive PCR test (polymerase chain reaction) result for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) 1-4 months before enrollment
• A fatigue score above 9 in the Chalder Fatigue scale upon enrollment
• Willing to fill out regular questionnaires
• Willing to use LDN and NAD patches

You may not qualify if…

• Clinically significant kidney, heart, Hepatic impairment as determined by clinical judgement
• Taking opioid analgesics, or undergoing treatment for opioid addiction
• Opioid dependence or withdrawal syndrome
• Known sensitivity to naltrexone
• Suspected or confirmed pregnancy or breastfeeding
• Known issues with using iontophoresis patches
• Active cancers
• Enrolled in another trial
• Current users of LDN or NAD+

Where it is running

• AgelessRx — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.